Cross-talk between PRMT1-mediated methylation and ubiquitylation on RBM15 controls RNA splicing
Zhang, Li ; Tran, Ngoc-Tung ; Su, Hairui ; Wang, Rui ; Lu, Yuheng ; Tang, Haiping ; Aoyagi, Sayura ; Guo, Ailan ; Khodadadi-Jamayran, Alireza ; Zhou, Dewang ... show 10 more
Citations
Authors
Tran, Ngoc-Tung
Su, Hairui
Wang, Rui
Lu, Yuheng
Tang, Haiping
Aoyagi, Sayura
Guo, Ailan
Khodadadi-Jamayran, Alireza
Zhou, Dewang
Qian, Kun
Hricik, Todd
Cote, Jocelyn
Han, Xiaosi
Zhou, Wenping
Laha, Suparna
Abdel-Wahab, Omar
Levine, Ross L.
Raffel, Glen
Liu, Yanyan
Chen, Dongquan
Li, Haitao
Townes, Tim
Wang, Hengbin
Deng, Haiteng
Zheng, Yujun George
Leslie, Christina
Luo, Minkui
Zhao, Xinyang
Student Authors
Faculty Advisor
Academic Program
Document Type
Publication Date
Keywords
Subject Area
Embargo Expiration Date
Link to Full Text
Abstract
RBM15, an RNA binding protein, determines cell-fate specification of many tissues including blood. We demonstrate that RBM15 is methylated by protein arginine methyltransferase 1 (PRMT1) at residue R578 leading to its degradation via ubiquitylation by an E3 ligase (CNOT4). Overexpression of PRMT1 in acute megakaryocytic leukemia cell lines blocks megakaryocyte terminal differentiation by downregulation of RBM15 protein level. Restoring RBM15 protein level rescues megakaryocyte terminal differentiation blocked by PRMT1 overexpression. At the molecular level, RBM15 binds to pre-mRNA intronic regions of genes important for megakaryopoiesis such as GATA1, RUNX1, TAL1 and c-MPL. Furthermore, preferential binding of RBM15 to specific intronic regions recruits the splicing factor SF3B1 to the same sites for alternative splicing. Therefore, PRMT1 regulates alternative RNA splicing via reducing RBM15 protein concentration. Targeting PRMT1 may be a curative therapy to restore megakaryocyte differentiation for acute megakaryocytic leukemia.
Source
Elife. 2015 Nov 17;4. pii: e07938. doi: 10.7554/eLife.07938. Link to article on publisher's site